Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19828012 | 1.00 | CYP3A4 (0.40) | CYP3A4CYP2C9ADORA3ADORA1ADORA2B | |
| SCHEMBL19822460 | 0.93 | CYP3A4 (0.40) | CYP3A4CYP2C9ADORA3ADORA1BTN3A1 | |
| SCHEMBL19828009 | 0.90 | ADORA3 (0.36) | CYP3A4CYP2C9ADORA3ADORA1ADORA2B | |
| SCHEMBL19822461 | 0.89 | CYP3A4 (0.40) | CYP3A4CYP2C9ADORA3ADORA1P2RY1 | |
| SCHEMBL21137191 | 0.87 | CYP3A4 (0.47) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL18067100 | 0.85 | CYP3A4 (0.55) | CYP3A4CYP2C9ADORA3ADORA1ADORA2B | |
| SCHEMBL21101684 | 0.85 | CYP3A4 (0.55) | CYP3A4CYP2C9ADORA3ADORA1ADORA2B | |
| SCHEMBL19644780 | 0.85 | CYP3A4 (0.55) | CYP3A4CYP2C9ADORA3ADORA1ADORA2B | |
| SCHEMBL18067101 | 0.85 | CYP3A4 (0.55) | CYP3A4CYP2C9ADORA3ADORA1ADORA2B | |
| SCHEMBL19833071 | 0.85 | CYP3A4 (0.55) | CYP3A4CYP2C9ADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005811-B2 | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005811-B2 | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180030082-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
| US-20180030082-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005811-B2 | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | CYP3A4 3492/4885CYP2C9 3976/4885ADORA3 52/4885 |
| US-20180030082-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | CYP3A4 3731/4885CYP2C9 3994/4885ADORA3 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.